Clinical Trial

Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas

Study acronym: RRTCLAlloSCT
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 18, 2022 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
Relapsed and refractory T-cell lymphomas have been reported to have dismal outcomes. The role of allogeneic stem cell transplantation have been demonstrated in these patients. This clinical trial is studying the efficacy and safety of busulfan plus fludarabine as conditioning therapy followed by allogeneic stem cell transplantation (Allo-SCT) in T- and NK/T-cell lymphoma patients who have relapsed or are refractory to previous chemotherapies including autologous transplantation.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2016-08-08; most recent amendment 2022-08-17.
Status change: Not Yet Recruiting → Recruiting 2017-01-31
Trial Details
NCT Number NCT02859402
Lead Sponsor Keimyung University Dongsan Medical Center
Collaborators: Otsuka Pharmaceutical Co., Ltd.
Conditions T-cell Non-Hodgkin Lymphoma, Lymphoma, Extranodal NK-T-Cell
Enrollment 34 participants
Start Date 2016-12
Primary Completion 2025-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2022-08-18